Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04251663 · ClinicalTrials.gov registry record
Complement C5a Receptors in Hidradenitis Suppurativa
A clinical trial, sponsored by Stanford University.
- Completed
- Registry status
- 34
- Enrollment target
NCT04251663: Completed study, sponsored by Stanford University.
NCT04251663 is a clinical trial that has completed, run by Stanford University. The registered enrollment target is 34 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04251663 has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- 34 participants
- Enrollment target
Study Summary
To study the role of C5a in Hidradenitis Suppurativa (HS). Complement C5a is a major chemotactic factor that stimulates neutrophil infiltration.
Primary Outcome
Relative expression of adhesion molecule (CD11b) on circulating neutrophils in HS patients determined by flow cytometry.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2019-07-18 |
| Est. Completion | 2022-07-29 |
What the finished NCT04251663 record still lists
NCT04251663 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 34 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT04251663 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04251663 about?
NCT04251663 is a clinical study titled "Complement C5a Receptors in Hidradenitis Suppurativa". To study the role of C5a in Hidradenitis Suppurativa (HS). Complement C5a is a major chemotactic factor that stimulates neutrophil infiltration.
What is the current status of trial NCT04251663?
This trial is currently completed. The enrollment target is 34 participants. The study started on 2019-07-18. Estimated completion is 2022-07-29.
Who is sponsoring clinical trial NCT04251663?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02897063 · 34 participants · Phase 1
Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure
- NCT03906617 · 34 participants · Phase 4
Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine
- NCT03992378 · 34 participants · NA
Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis
- NCT04047849 · 34 participants · Phase 4
Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI